GlaxoSmithKline and Medivir Announce Licensing Agreement on Antiviral Compound
20. Mai 2003 14:00 ET
|
Medivir
HUDDINGE, Sweden, May 20, 2003 (PRIMEZONE) -- GlaxoSmithKline (NYSE:GSK) and Medivir today announce that they have signed a licensing agreement for MIV-210, a nucleoside analogue reverse...
Medivir Interim Report Q1, 2003
29. April 2003 09:18 ET
|
Medivir
HUDDINGE, Sweden, April 29, 2003 (PRIMEZONE) -- Medivir
- MIV-210 producing positive results in ongoing phase I trial.
- More opportunities for Cathepsin S inhibitor.
- Successes in the...
Medivir's Research Partner, Peptimmune, Attracts US $41.2m From Investors
14. März 2003 08:40 ET
|
Medivir
HUDDINGE, Sweden, March 14, 2003 (PRIMEZONE) -- Medivir (Stockholm:MVIRb):today announced the American biotech corporation, Peptimmune, has recently obtained US $41.2 million from American investors....
Medivir: Financial Statement for 2002 -- January-December 31, 2002
14. Februar 2003 08:14 ET
|
Medivir
HUDDINGE, Sweden, Feb. 14, 2003 (PRIMEZONE) -- Medivir (Stockholm:MVIRb):
- MIV-606 (now RP-606) outlicensed to Reliant Pharmaceuticals in
February
- MV026048 outlicensed to Roche...
Medivir's MIV-210 Enters Phase I Multiple Dose Study
07. Februar 2003 05:09 ET
|
Medivir
HUDDINGE, Sweden, Feb. 7, 2003 (PRIMEZONE) -- The continued phase I clinical study, multiple dosing in healthy volunteers, for the antiviral MIV-210 has now started. The study is being performed in...
New CEO in Medivir
31. Januar 2003 03:30 ET
|
Medivir
HUDDINGE, Sweden, Jan. 31, 2003 (PRIMEZONE) -- The Board of Medivir (Stockholm:MVIRb) has appointed Lars Adlersson to the position as CEO and President beginning March 1, 2003.
Lars Adlersson is 38...
Medivir Appoints Acting CEO
20. Dezember 2002 08:16 ET
|
Medivir
HUDDINGE, Sweden, Dec. 20, 2002 (PRIMEZONE) -- The Medivir (Stockholm:MVIRb) Board has appointed Professor Bo Oberg, Ph.D., as acting CEO as of January 1, 2003. The process to appoint a permanent CEO...
Medivir and Paradigm Enter Alliance
13. Dezember 2002 08:25 ET
|
Medivir
HUDDINGE, Sweden, Dec. 13, 2002 (PRIMEZONE) -- Medivir and Paradigm Therapeutics Ltd (Cambridge, U.K.) have entered a broad-based, 3-year research collaboration to identify novel protease drug...
Medivir's Interim Report 3
04. November 2002 06:36 ET
|
Medivir
HUDDINGE, Sweden, Nov. 4, 2002 (PRIMEZONE) -- Medivir (MVIRb):
- MIV-310 has demonstrated powerful anti-viral activity on patients with
multiresistant HIV that do not respond to current drugs....
Positive Results for Medivir's Project MIV-210 Presented at ICAAC
30. September 2002 04:12 ET
|
Medivir
HUDDINGE, Sweden, Sept. 30, 2002 (PRIMEZONE) -- Medivir's (Stockholm:MVIRb) antiviral MIV-210 is active against HIV and HBV (hepatitis B virus, viral jaundice) and is in phase I clinical trials. The...